Preventing Asthma in High Risk Kids

Prevention/ Disease modification of asthma.

Controlling and Preventing Asthma Progression and Severity in Kids

This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.

Preventing Asthma in High Risk Kids

Recruitment

Summary

Participation Requirements

Description

Tracking Information